跳至主要内容
临床试验/NCT02161146
NCT02161146已完成3 期

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

Allergan0 个研究点目标入组 240 人开始时间: 2014年6月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Allergan
入组人数
240
主要终点
Ocular Itching Score

研究概览

简要总结

This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Japanese patients living in Japan with a history of allergic conjunctivitis.

排除标准

  • Presence of active eye infection (bacterial, viral, or fungal)
  • History of an eye herpetic infection.

研究组 & 干预措施

AGN-229666/Olopatadine

Other

One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.

干预措施: AGN-229666 (Drug)

AGN-229666

Experimental

One drop of AGN-229666 in each eye on Days 1 and 15.

干预措施: AGN-229666 (Drug)

Vehicle

Placebo Comparator

One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15.

干预措施: Vehicle to AGN-229666 (Drug)

Olopatadine

Active Comparator

One drop of olopatadine in each eye on Days 1 and 15.

干预措施: Olopatadine (Drug)

AGN-229666/Olopatadine

Other

One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.

干预措施: Olopatadine (Drug)

AGN-229666/Vehicle

Other

One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.

干预措施: AGN-229666 (Drug)

AGN-229666/Vehicle

Other

One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.

干预措施: Vehicle to AGN-229666 (Drug)

结局指标

主要结局

Ocular Itching Score

时间窗: Days 1 and 15

Ocular itching was assessed by the participant 8 hours after AGN-229666 and vehicle administration and 4 hours after olopatadine administration, 5 minutes post allergen challenge using a 0 to 4 scale with 0.5 grade increments where: 0=none (no itching) to 4.0=incapacitating itch with an irresistible urge to rub (worst). Data from Days 1 and 15 were pooled together and averaged.

次要结局

  • Conjunctival Hyperemia Score(Days 1 and 15)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验